Welcome to our dedicated page for Abbvie SEC filings (Ticker: ABBV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
With operations spanning immunology, oncology, neuroscience, aesthetics, and eye care, AbbVie SEC filings reveal how one of biopharma largest companies allocates resources across its therapeutic divisions. Each quarterly 10-Q breaks down revenue by segment, showing which areas drive growth and which face competitive pressure from biosimilars and new market entrants.
AbbVie 10-K annual reports detail the company drug development pipeline, including clinical trial phases, anticipated FDA decision dates, and potential market size for each candidate. The R&D expense disclosures show investment priorities across therapeutic areas, while risk factor sections outline regulatory, competitive, and patent expiration challenges facing each product franchise.
Form 4 insider transaction filings track when AbbVie executives and directors buy or sell company shares. These transactions can signal management confidence in upcoming catalysts such as FDA approvals, clinical trial results, or strategic acquisitions. Our platform flags significant Form 4 activity automatically.
AbbVie 8-K filings announce material events including acquisition completions, major licensing agreements, FDA decisions, and leadership changes. For a company of AbbVie size and acquisition activity, 8-K filings often contain market-moving information about pipeline expansion and strategic direction.
The DEF 14A proxy statement reveals executive compensation structures, performance metrics tied to bonuses, and board composition details. For institutional investors, these disclosures inform governance assessments and say-on-pay voting decisions.
Our AI summaries translate complex pharmaceutical disclosures into clear explanations, highlighting revenue trends, pipeline updates, and segment performance without requiring hours of document review. Access real-time EDGAR updates for all AbbVie regulatory filings in one location.
AbbVie Inc. (ABBV) Form 144 notice: An insider proposes to sell 62,755 shares of common stock through Morgan Stanley Smith Barney LLC on 08/22/2025. The shares were acquired the same day via a stock option exercise and paid for in cash. The filing lists an aggregate market value for the proposed sale of $13,231,264.20 and reports 1,766,558,253 shares outstanding for the class. The filer also reported four prior common-stock sales in August 2025 by Richard A. Gonzalez: 61,500 shares on 08/01/2025 (gross proceeds $12,043,268.25), 35,120 shares and 91,600 shares on 08/04/2025 (gross proceeds $6,828,296.22 and $19,208,000.00 respectively), and 90,000 shares on 08/21/2025 (gross proceeds $18,993,947.76). The filer certifies no undisclosed material adverse information and acknowledges legal penalties for false statements.
AbbVie insider sale notice: This Form 144 shows that Richard A. Gonzalez intends to sell 90,000 AbbVie (ABBV) common shares through Morgan Stanley Smith Barney on 08/21/2025 with an aggregate market value of $18,993,947.76. The filing reports Abbies outstanding shares as 1,766,558,253, so the planned sale represents a small fraction of total shares. The 90,000 shares were acquired the same day, 08/21/2025, by stock option exercise and paid for in cash.
The filing also discloses recent insider sales by Richard A. Gonzalez during the past three months: 61,500 shares sold 08/01/2025 for $12,043,268.25; 35,120 shares sold 08/04/2025 for $6,828,296.22; and 91,600 shares sold 08/04/2025 for $19,208,000. The notice includes the standard insider representation that no undisclosed material adverse information is known.
Azita Saleki-Gerhardt, Executive Vice President and Chief Operations Officer of AbbVie Inc. (ABBV), reported transactions on 08/12/2025 showing she exercised employee stock options and simultaneously sold the resulting shares. She acquired 42,370 shares through exercise at a reported exercise price of $54.86 per share and sold 42,370 shares the same day at a weighted-average sale price of $198.42 per share. Following these transactions, her reported direct beneficial ownership decreased from 219,662 shares to 177,292 shares. The Form 4 notes 2,647 shares are held in an AbbVie savings program and 3,873 shares are held by her spouse (for which she disclaims beneficial ownership). The transactions were reported by an attorney-in-fact and the filing includes an explanatory footnote that the sale prices reported represent a range of prices between $198.34 and $198.58.
AbbVie filed a Form 144 reporting a proposed sale of 42,370 shares of common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $8,407,068.11. The filing lists the approximate date of sale as 08/12/2025 and shows the shares were acquired by a stock option exercise on 08/12/2025 with payment in cash.
The notice states there were no securities sold in the past three months by the person for whose account the shares are to be sold. The filing includes the total number of shares outstanding as 1,766,558,253, and identifies the executing broker and the class of security as common stock. No additional transaction context or identities are provided in the document.
AbbVie (ABBV) filed a Form 144 reporting proposed sales of common stock through Northern Trust Securities on the NYSE. The notice lists three proposed transactions: 61,500 shares (aggregate market value $12,043,268.25, approx. sale date 08/01/2025), 35,120 shares ($6,828,296.22, 08/04/2025) and 91,600 shares ($19,208,000, 08/04/2025). The filing shows a reported number of outstanding shares of 1,766,558,253.
The document discloses the acquisition history for the securities to be sold, showing they were received as restricted stock in grants dated between 02/28/2017 and 02/26/2021 with specific grant amounts listed. The filer indicates no securities sold in the past three months and includes the standard Rule 144 attestation about lack of undisclosed material adverse information.
FAQ
What is the current stock price of Abbvie (ABBV)?
What is the market cap of Abbvie (ABBV)?
